Johnson Matthey Inspiring science, enhancing life

Capital Markets Day Sustained growth and value creation

10000000

September 2017

Cautionary statement

This presentation contains forward looking statements that are subject to risk factors associated with, amongst other things, the economic and business circumstances occurring from time to time in the countries and sectors in which Johnson Matthey operates. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a wide range of variables which could cause actual results to differ materially from those currently anticipated.

Agenda

Start	Session	Presenters
9:30am	Sustained growth and value creation	Robert MacLeod
9:50am	Clean Air and Q&A	John Walker and Phil Blakeman
11:00am	Break	
11:30am	Battery Materials and Q&A	Alan Nelson
12:15pm	Lunch	
1:00pm	Efficient Natural Resources and Q&A	Jane Toogood
1:40pm	Health and Q&A	Robert MacLeod, Garrett Dilley and Paul Evans
2:30pm	Break	
3:00pm	Delivering shareholder value	Anna Manz
3:20pm	Concluding remarks and Q&A	Robert MacLeod

Restatement

Clean Air	Emission Control Technologies	Reallocation	Clean Air	% of Group
For year ended 31 st March 2017				
Sales excluding precious metals (£m)	2,224		2,224	60%
Underlying operating profit (£m)	318.2		318.2	62%
ROS (%)	14.3		14.3	
ROIC (%)	30.7		30.7	

Efficient Natural Resources	Process Technologies	Precious Metal Products	Reallocation	Efficient Natural Resources	% of Group
For year ended 31 st March 2017					
Sales excluding precious metals (£m)	587	403	(71) ⁽¹⁾	919	25%
Underlying operating profit (£m)	90.4	86.4	(13.8) ⁽²⁾	163.0	32%
ROS (%)	15.4	21.4		17.7	
ROIC (%)	11.4	19.8		13.5	

Restatement

Health	Fine Chemicals	Reallocation	Health	% of Group
For year ended 31 st March 2017				
Sales excluding precious metals (£m)	284	(48) (1)	236	7%
Underlying operating profit (£m)	64.5	(12.8) (1)	51.7	10%
ROS (%)	22.8		21.9	
ROIC (%)	12.3		10.4	

1. Catalysis and Chiral Technologies

New Markets	New Businesses	Reallocation	New Markets	% of Group
For year ended 31 st March 2017				
Sales excluding precious metals (£m)	191	117 (1)	308	8%
Underlying operating profit / (loss) (£m)	(14.4)	26.6 ⁽²⁾	12.2	2%
ROS (%)			4.0	
ROIC (%)			6.2	

£61m medical sales, £48m Catalysis and Chiral Technologies and £8m intersegment sales
 £13.8m Medical profit and £12.8m Catalysis and Chiral Technologies profit

Johnson Matthey Inspiring science, enhancing life

Sustained growth and value creation

20000000

Robert MacLeod Chief Executive

Sustained growth and value creation through:



Solving complex problems across the group with world class chemistry

Materials characterisation and testing



PGM chemistry and metallurgy



Material design and engineering



Surface chemistry



and its application





Development of new and next-generation products



Scale-up of complex manufacturing

JM

Provision of customised solutions

We address three big global challenges

Improving air quality The efficient use and transformation of natural resources

Improving healthcare

Increasing concern by consumers and governments on **Clean Air** Growing population and consumer aspiration is increasing demand for Efficient use of Natural Resources

Need for affordable Health care which is increasingly personalised

How to reduce powertrain emissions as efficiently as possible How to achieve greater efficiency and optimal yields in the use of natural resources How to make complex, often highly potent APIs, efficiently and quickly

Technology leadership gives us #1 positions



Sustained growth and value creation



JM

Sustained growth and value creation through:



Clear visibility of sustained growth in Clean Air

Heightened air quality issues causing rapid change

In Europe Light Duty:

- In short term, we grow strongly from substantial share gains
- ICE powertrain and legislation substantially reduces diesel/gasoline share sensitivity

Asia transforms in scale

North America grows steadily

Margins maintained through focus on efficiency



Breakout growth in Health from a deeper, broader API portfolio

We have established positions in attractive, growing market

Increasing API complexity/generic penetration play to JM strengths

Our growth will come from:

- Our existing portfolio will outperform
- Our new product pipeline in generics adds c.£100m OP in 2025
- Building on strong reputation for driving development and commercialisation
- Enhancing our growth by entering adjacent segments



Breakout growth in Battery Materials through technical leadership

Market is still in its early stage but the opportunity is substantial

We have already developed materials with market leading performance characteristics

We will invest in high energy manufacturing capacity, starting in 2018/19



Outperformance in targeted, growth segments in Efficient Natural Resources

Market has changed significantly in recent years

We have leading positions in most markets

We will outperform in higher growth segments

Increased efficiency of operations will enhance performance



We create value by investing in our technology through three stages

Stage	Clean Air	Efficient Natural Resources	Health
Selectively invest through New Markets sector	e.g. Battery Materials	e.g. Agrochemicals	e.g. Medical Devices
Scale-up	e.g. Emission Control in Asia	e.g. PGM Refining in China	e.g. API Manufacturing in both Innovators and Generics
Sustain and grow	e.g. Emission Control in Europe & NA	e.g. Hydrogen catalysts	-

Sustained growth and value creation through:

Improving performance through common standards and simplified processes

Accelerated by IT enablement

Creating a business that is more robust and more agile

Releasing £50m of cost over the next 3 years for reinvestment and margin expansion

Relentless focus on driving efficiency



Our vision is for a cleaner and healthier world

By 2025, we will:

Enhance technology leadership in our targeted markets

JM

Have three substantial and growing sectors Have excellence in everything we do

Be one of the best performing, most trusted and admired speciality chemicals companies in the world



Johnson Matthey Inspiring science, enhancing life

Clean Air: Sustained growth and value creation from a global leader

JM

John Walker – Sector Chief Executive, Clean Air Phil Blakeman, Ph.D. – Managing Director, Clean Air Sector, Asia

Sustained growth and value creation from a global leader

Europe Light Duty grows strongly in short term and broadly flat over 10 years

North America Light Duty delivers consistent growth

Asia transforms in scale

Operational efficiency supports margin and ROIC

Mid single digit sales CAGR over next decade

Our Sector strategy assumes:

Impact of legislation only included Euro 7/VII is likely to drive increased where quantifiable value per vehicle but is not included Diesel share declining to 25%* of Every 1ppt decline below 25% would Western Europe by 2025 impact gross profit by \sim £4m Neutral for gasoline to gasoline hybrid Increased penetration of hybrids or diesel to diesel hybrid Global BEV penetration increasing Every 1ppt increase above 6% would impact gross profit by ~£7m to 6% by 2025

Sales grew at 11% CAGR over last 5 years

Sales 2016/17 by sub-business¹



JM

Other

1 Sub-businesses restated: South American businesses transferred from Europe to Americas, Americas LD truck business transferred from Heavy Duty to Light Duty, Heavy Duty includes non road

Share gains and tighter legislation gives visibility of mid single digit CAGR over 10 years

1-2 Years	3-6 Years	7-10 Years	
Strong growth driven by:	Good growth driven by:	Growth driven by:	
 Additional ~20 ppts share secured in Europe 	 Tightening legislation in Asia and Europe 	 Tightening legislation in US 	
Light Duty diesel	Partly offset by:	Partly offset by:	
 Tightening legislation in Europe 	 Continued Europe diesel decline and early BEV penetration 	 Faster BEV penetration and further Europe diesel decline 	

Four key Clean Air segments to discuss



Europe Light Duty – Broadly flat over 10 years following strong short term growth

Sales 2016/17



Vehicle production		
Air quality		
JM share		
Hybrid / diesel / gasoline		
BEV		

Europe LDV

- Americas LDV
- Asia LDV
- Europe HDV
- Asia HDV
- Americas HDV
- Other

01. Vehicle production expected to grow but is not a material driver of growth

2% p.a. vehicle growth impacted by:

Population +

Increased wealth +

Better public transport -

Car sharing / ride hailing -



02. Air quality drives tighter legislation which adds value per vehicle

Gasoline : Sales per vehicle increases significantly

Euro 6b

Three way catalyst x2



Euro 6c/d

Three way catalyst + gasoline particulate filter

~2x value per vehicle

GPFs expected on >90% of GDI vehicles by 2025 GDI vehicles expected to be 80% of gasoline

Diesel : Sales per vehicle increases Euro 6b Diesel oxidation catalyst + catalysed soot filter + selective catalytic reduction Euro 6c/d Luro 6c/d Advanced selective catalytic reduction Up to 1.5x value per vehicle

JM

03. Fundamental change in emission control market led to significant increase in JM share



NOx emissions in the public spotlight

OEMs moved quickly to improve emissions ahead of legislation



03. Our leadership in diesel technology and fast response led to share gains

Our technology delivers significant decrease in NOx emissions

Excellent low temperature NOx conversion

Outstanding thermal durability

Strong customer relationships and manufacturing agility



JM diesel share increases by ~20 ppts in 2018/19

03. In addition our gasoline filter technology is driving material share gains



JM gasoline share will increase by ~5 ppts as Euro 6d phases in

04. Demand for diesel and gasoline ICEs increasingly impacted by consumer behaviour

Consumer awareness of vehicle emissions has increased

Consumer are moving through a spectrum:

- From: diesel to gasoline
- From: ICE to hybrids
- To: EV



04. Hybrids will become a significant part of the market

Consumers

OEMs

Hybrid offers fuel efficiency for small vehicles and urban driving

Hybrids needed to manage fleet average CO₂

Opportunity for more complex systems to manage stop / start engines

Neutral impact on Clean Air



04. Diesel / diesel hybrid share of light duty Western Europe is assumed to decline to 25%* by 2025



Mix of pure diesel ICE and diesel hybrids

Majority of cars assumed to be hybrids by 2025

04. For JM, the sales gap between diesel and gasoline will halve

Ratio of diesel to gasoline value per vehicle

JM



Sales ex pm diesel to gasoline ratio

A 1ppt shift from diesel to gasoline (including gasoline hybrids) impacts gross profit by ~£4m



04. Share gains in a growing gasoline market



Gasoline - including hybrid vehicle production to increase 4% p.a.

Legislation approximately doubles sales value for some gasoline vehicles

JM share of gasoline market increases ~5 ppts by 2020/21

JM
05. BEVs will take share from traditional powertrains





Europe Light Duty summary

Key Driver

Vehicle production	2% CAGR supports growth in sales					
Air quality - legislation	Euro 6c/d adds ~2x value for most gasoline vehicles					
JM share	Technology leadership and agility drive share gains in diesel \sim 20ppt and gasoline \sim 5ppt					
Diesel/gasoline share	Diesel market share declines to 25%* of Western Europe light duty by 2025					
Hybrids	Penetration significantly increases to manage average fleet CO_2 with neutral impact on Clean Air					
BEV penetration	9% by 2025					

Europe Light Duty broadly flat over 10 years following strong short term growth

38

Americas Light Duty – Steady growth over the next decade

Sales 2016/17





Europe LDVAmericas LDV

- Asia LDV
- Europe HDV
- ■Asia HDV
- Americas HDV
- Other

01. Vehicle production will grow marginally

Vehicle growth impacted by:

Population +

Car sharing / ride hailing -

Diesel and BEV make gains



02. Legislation tightens adding sales value per vehicle

US legislation tightens for particulate matter

 % of fleet required to meet standard increases over time

Technology adds value further out

 Filters for some gasoline vehicles from ~2024 (assumed low fitment rate)

LEVIII particulate matter standards and fleet compliance rate



03. Expect to win share through technology in a growing diesel market

OEMs offering greater numbers of diesel variants

Increasing demand for diesel pick-ups, SUVs and crossovers

Diesel attractive option to meet tightening fuel economy standards

Strong technology provides scope for JM's diesel share to increase



04. BEV to have marginal impact in next 10 years



Americas Light Duty summary

Key Driver

Vehicle production	Marginal growth supports growth in sales
Air quality - legislation	GPF adoption expected from 2024 from tighter particulate matter legislation
Diesel/gasoline share	JM technology leadership supports share gains in growing diesel market
BEV penetration	Low level BEV penetration supports growth in sales

Steady growth over the next decade



Clean Air – Asia Light Duty and Global Heavy Duty Phil Blakeman, Ph.D. – Managing Director, Clean Air Sector, Asia



Asia Light Duty – Short to medium term growth from tighter legislation will almost double Asia Light Duty in 10 years

Sales 2016/17





Other

Europe LDVAmericas LDV

Americas HDV

Asia LDV
Europe HDV
Asia HDV

01. China vehicle production growth of 2% p.a. supports sales growth

Vehicle growth impacted by:

Relatively low vehicle ownership rate +

Increased wealth +

But will lag economic growth due to:

Increased urbanisation and improvements in public transport -

Usage barriers (esp. big cities) & ownership trends -



02. China air quality focus brings legislation which doubles sales value per vehicle



China 5 gasoline

Three way catalyst x2



China 6a gasoline from July 2020

Three way catalyst + gasoline particulate filter (GPF)

China 6b gasoline from July 2023

Three way catalyst + gasoline particulate filter (GPF)

~2x China 5

Real world driving

JM has the technology to deliver to these standards

03. China BEV growing fast and impacts growth in later years



04. Other Asian countries provide additional growth

India grows strongly

- Strong growth in vehicle production
- BS 6 legislation from April 2020:
 - Gasoline remains with three way catalyst only
 - Increase in technology on diesel cars partly offset as diesel market share declines

Japan stable

- Steady car production
- Key for maintaining our relationships with Japanese OEMs

South East Asia growth

• Tightening vehicle regulations across the region provide opportunities for growth

Asia Light Duty summary

Key Driver

China vehicle production	2% CAGR supports growth in sales			
China Air quality - legislation	China 6a and China 6b doubles sales value for some vehicles			
China BEV penetration	13% by 2025			
Other Asia	Growth from tightening legislation in India and South East Asia			

Asia Light Duty to nearly double sales over the next 10 years

Global Heavy Duty- Legislation in China and India drives growth over the next 10 years

Sales 2016/17



Other



01. Global truck production growth of2% p.a. supports growth

US low single digit growth with cyclical class 8 trucks

Europe mid single digit growth

China marginal growth

India grows in line with GDP



02. Asia legislation triples sales value per vehicle in China and India

China V

Selective catalytic reduction + ammonia slip catalyst





China VI

diesel oxidation catalyst + catalysed soot filter + selective catalytic reduction + ammonia slip catalyst **From January 2021 (expected)**

~3x China V

India BS IV

Diesel oxidation catalyst or selective catalytic reduction





India BS VI

Diesel oxidation catalyst + catalysed soot filter + selective catalytic reduction + ammonia slip catalyst **From April 2020**

~3x India BS IV

Scope for share gains from our technology and focus on diversifying customer base to Asian OEMs

03. Expect BEV to have minimal impact over next 10 years

Interest in truck electrification but early technology solutions not suitable for majority of market

Limited by economic calculation of weight of freight carried versus total cost of ownership

Broad range of possible outcomes in the longer term



Global Heavy Duty summary

Key Driver

Truck production	2% CAGR supports growth in sales				
Air quality - legislation	China VI / India VI drive significant increase in technology and triples sales value per vehicle				
BEV penetration	Minimal impact on sales growth				

Sustained growth in global Heavy Duty driven by legislation in China and India



Clean Air John Walker – Sector Chief Executive, Clean Air



Opportunities to drive efficiency



Consistent value creation from a global leader

Europe Light Duty broadly flat absorbing decline in diesel share of market and BEV penetration

Americas Light Duty grows steadily with limited BEV penetration Good growth in Asia Light Duty despite strong BEV penetration

Sustained growth in global Heavy Duty driven by legislation in Asia

Improved operational efficiency supports margin

Mid single digit sales CAGR over the next 10 years in Clean Air

JM

Johnson Matthey Inspiring science, enhancing life

Battery Materials: Delivering breakout growth

Alan E Nelson, Ph.D., P.Eng. Sector Chief Executive, New Markets and Group CTO

New Markets: three businesses at scale, focus on battery materials



Become a leader using our chemistry advantage and JM capabilities

Flexibility across hybrid, BEV and fuel cell technologies

Battery materials the most developed opportunity



Become a leader in pharma and agchem catalysts and processes

Cross-selling technologies with our Health sector

Expanding opportunities in new markets

Medical Device Components



Become a leader in the development of medical device components

Collaborate with customers to provide innovative solutions

Significant progress in development of high energy battery materials



The evolution of the automotive powertrain faces many challenges



OEMs focused on bringing affordable long range xEVs to market

"Ford is...adding 13 new electrified vehicles to its product portfolio by 2020; more than 40 percent of Ford's name plates globally will be electrified by the decade's end"

Press release, December 2015

"All models launched after 2019 will have a hybrid or fully electric propulsion"

Håkan Samuelsson, Volvo CEO H1 Results, July 2017 "We are now focusing on the electrification of our core portfolio and the introduction of BEV models through the 2019-2021 period"

BMW Group Investor Presentation, August 2017 "Volkswagen is...launching more than 30 purely battery-powered electric vehicles over the next ten years... BEV sales will be...equivalent to some 20 to 25 percent of the total unit sales expected at that time"

Volkswagen, Strategy 2025, June 2016

Today xEV adoption is limited by total cost of ownership

Total cost of ownership (TCO) for passenger cars, Europe 2017¹



- xEV penetration today driven by government subsidy
- xEVs are forecast to reach TCO parity in the mid 2020s, depending on vehicle segment
- Cost of lithium ion batteries has declined over the past decade
- Cathode materials over this time have not changed significantly

Demand for cathode materials between \$15bn and \$100bn by 2025

Projected xEV (BEV and PHEV) global light duty vehicle powertrain share 2015-2025,%¹



- Estimates of xEV (BEV and PHEV) penetration range from 4% - 25% by 2025
- ICE and mild hybrids still expected to dominate market for the **medium term**
- Projected automotive cathode materials market by 2025:
 - **\$15bn-\$100bn** of sales
 - 500k to 3.3m metric tons of capacity required, c. 150k today for automotive markets

A range of materials are required

Powertrain implications on cathode volumes and chemistries¹

		Micro HEV	HEV	PHEV	EV Medium	EV Long	PHEV-bus	E-Bus
Material demand ¹	Ave. Pack size (kWh)	0.6	1.0	10	30	70	70	250
	Cathode (kg), approx.	c.1	c.2	c.20	c.50	c.120	c.120	c.400
Materials positioning	LFP	High power					Safety a	nd cost
	NMC / NCA	I	High energy and range					
JM eLNO		High energy, range, cost and safe				ty		

JM is addressing the challenges for the adoption of xEVs



JM focus:

Technology investment

Broad portfolio of cathode materials

Sustained cathode materials innovation

Building manufacturing capacity

Addressing cost (\$/kWh)

High energy material with low cobalt

Addressing barriers in the supply chain

JM has a strong position in the value chain



Raw materials: strategic sourcing of metals



- JM-wide longstanding history of metals procurement and management
- Leveraging nickel and cobalt contracts and buying power with Efficient Natural Resources
- Strategic partnership with Nemaska Lithium for the supply of lithium
- Developed advanced precursors to enable starting production from raw metals

Electrodes, cells, and systems: insights to drive materials innovation





 Understanding electrode structures to design cathode material morphology to improve energy density

• Understanding cell performance to **match cathode performance** with anode, electrolyte, and separator



 Understanding pack-level performance to improve cathode materials lifetime and safety

Cathode materials: using our chemistry to develop leading materials



- IP across a range of battery materials: LNO, NMC, and LFP
- Over 60 R&D scientists
- Leveraging **nickel expertise** across JM
- Using **Clean Air expertise** in materials engineering and understanding automotive qualification cycles
- **Strategic partnerships** with cell manufacturers and automotive OEMs
Significant progress in high energy materials in the past year

May 2016 • Licensed key high nickel intellectual property

Developed high energy cathode materials and scaled-up to pilot scale

- Validated benefits of materials with cell manufacturers and OEMs
- Materials in qualification cycles with six customers
- Identified manufacturing sites for our plants
- Approved investment for demonstration scale manufacturing facility
- Investment on first plant of c.£200m from mid-2018

2017

We have a wide portfolio of battery materials including JM eLNO



JM eLNO delivers a step-change in performance





JM Battery material development focussed on beyond NMC materials

JM eLNO a step-change increase in energy density

Energy density¹



- eLNO will enable longer range EVs with lower pack level cost
- Step-change increase in energy density compared to NMC(622), NMC(811) and NCA materials
- Material can be further optimised for any customer automotive application
- Technology is a key driver for market share gain and margin capture

JM eLNO delivers outperformance against all other key metrics

Relative performance across key areas¹ Range Cycle life **Target Cost** Low temp **Safety** power Power •NMC622 — NMC 8,1,1 — NCA 80%Ni -elno

- On every key metric eLNO is the best material in the market
- eLNO delivers improvements across energy density, power, range, life cycle and safety
- Cost advantaged through the efficient thrifting of cobalt

Customers have validated the performance of JM eLNO

versus NMC	versus NCA
"delivered higher energy density than NMC(811)"	"shows improved power performance than NCA"
"delivered better rate capability than NMC(811)"	"improved low temperature power performance than NCA"
"cycle life equivalent to or greater than NMC(111)"	"shows higher capacity retention than NCA"

Feedback from leading cell manufacturers and OEMs

Market timeline for the commercialisation of battery materials

Qualification stage	Typical volume per stage	Milestones	Timeline
Initial testing	10 – 100 kg	Validation of cathode material performance	3 - 6 months
Cell performance	1 – 2 MT	Full range of materials testing under different conditions	Year 1
Selection and award	100 – 200 MT	Technical and commercial review and selection	Year 1 - 2
Scale-up	500 – 1000 MT	Preparation for full scale manufacturing for platform	Year 2 - 3
Commercial launch	> 2,500 MT	Commercial launch of vehicle platform	Year 3 - 5

JM manufacturing plans for high energy eLNO

Production volume	Investment start date	Start of production	Milestones
5 MT	2016	Today	Samples to multiple customers from JM asset
10 MT	2017	2018	Pilot plant qualification materials to customers
500 MT	2017	2019	Demo plant qualification materials to customers
10,000 MT	2018	2021	JM commercial plant production for materials
> 10,000 MT			Additional commercial production based on demand

Conclusion

- We have developed best-in-class high energy battery materials
- Investment of c.£200m from mid-2018 to manufacture up to 10,000 metric tons from FY21/22
- We expect to be on automotive platforms in production from FY21/22



JM

Johnson Matthey Inspiring science, enhancing life

Efficient Natural Resources: Outperformance in targeted, growth segments

Jane Toogood Sector Chief Executive, Efficient Natural Resources

Efficient Natural Resources:



Efficient Natural Resources : bringing together Process Technologies and Precious Metal Products

	Process Technologies	Precious Metal Products	Reallocation	Efficient Natural Resources	% of Group
For year ended 31 st March 2	017				
Sales excluding precious metals (£m)	587	403	(71) ⁽¹⁾	919	25%
Underlying operating profit (£m)	90.4	86.4	(13.8) ⁽²⁾	163.0	32%
ROS (%)	15.4	21.4		17.7	
ROIC (%)	11.4	19.8		13.5	

1. Removing £61m of Noble Metals medical sales and £10m intra sector sales

2. Removing Noble Metals medical

What you will hear today



We create value from the efficient transformation and use of natural resources:



Demand for the world's natural resources is increasing



Efficient Natural Resources enables our customers to use natural resources more efficiently



Using JM's core chemistry and technology expertise to solve complex and variable problems through close collaboration with customers



We serve four market sectors creating value through technology and customer service

Efficient Natural Resources 2016/17 sales by sub-business



PGM Services

Advanced Technologies

Catalyst Technologies			
Chemicals	Oil & Gas		
Chemical catalysts and process technology	Refinery catalysts and gas purification		
40% of Sector sales	23% of Sector sales		
PGM Services	Advanced Glass Technologies		
Precious metal products, recycling and business solutions Providing metal and metal products to the JM Group	Advanced glass materials and conductive inks for use in automotive glass and other industries		
27% of Sector sales	10% of Sector sales		

We use our technology to lead the market



We deliver outstanding customer service



Leveraging our competences to provide efficient transformation and use of natural resources



Our core strengths underpin #1 or #2 market positions in almost all our key segments



all markets

90

Increased demand for efficient use of natural resources

MegaTrends



Market Dynamics

Global growth 3% Oil price lower for longer Automotive production growth Increasing PGM recycle & reuse Over capacity in chemicals High growth regions Shift to clean, cheap feeds More environmental legislation Plastics growth

Differentiated approach given range of growth in markets

	Underlying medium term industry market growth	Average medium term growth rate in segments that JM operate in	Range of growth rates in segments that JM operate in
Chemicals	↑ 2-3%	2.5%	2 - 4.5%
Oil & Gas		2%	0.5 - 3%
AGT	2%	2.5%	2 - 3.5%
PGMS		Low single digit growth	

Platinum Group Metals: a secure & sustainable source of critical raw materials to JM Group and customers



JM strategy capitalises on current market trends

MegaTrends



Market Dynamics

Global growth 3% Oil price lower for longer Automotive production growth Increasing PGM recycle & reuse Overcapacity in chemicals

High growth regions Shift to clean, cheap feeds More environmental legislation Plastics growth

Implications for strategy

Change

Drive efficiency Increasing PGM recycle & reuse Maintain in depth customer process insight

Focus on high growth markets
Bigger footprint in high growth regions
Shift in PGM demand & mix
Fewer licenses, more catalysts
More gas and bio-based opportunities

Our strategy to deliver consistent market outperformance

Maximise growth through differentiated investment by segment and region and focus on margin retention in lower growth markets Focused investment in R&D to maintain & extend technology leadership

Deliver additional value through focus on efficiency Explore long term growth opportunities by extending our capabilities into adjacent markets, geographies and technologies



1. Maximise growth through deep understanding by segment and region

% of sales⁽¹⁾ in each growth area⁽²⁾



Increasing investment

96

2. Focused investment in R&D to maintain and extend technology leadership

Unique set of materials science and scale up capabilities

Maintain R&D spend at consistent level

R&D closely aligned to value creating sector positions and growth areas

Working closely with leading edge partners and customers to deliver step change innovation

Add value to our customer's operations through new data driven insights

Core shell reformer catalyst Optimised metal content, same performance





New methods of fabrication for PGMs using additive layer manufacturing



3. Deliver additional value by focus on efficiency

Enablers for Efficient Natural Resources

Operational Improvements

Complexity reduction

Organisational efficiencies

Examples

PGM refinery optimisation

Portfolio Optimisation

Spans & layers

Deliver Operational Improvement - Operating profit 1% ahead of sales growth

4. Explore long term growth opportunities by extending our capabilities into adjacent markets, geographies and technologies



New natural resource landscape

Exploring new market spaces

Alternative feedstocks

Gas to chemicals Biorenewables **Customer and circular economies** Recycling New customer solutions

Consortium to commercialise technology for low carbon chemicals and fuels



Strategic consortium

Develop and scale up of Virent BioForming® Technology

Aim to deliver a commercial facility to produce cost effective, bio-based fuels and bio-paraxylene

The future for Efficient Natural Resources means:

A wider scope building on JM core competencies and leadership in chemistry and technology

Performance improvement by focussed investment and efficiency

Sales growth at 1% above the market (excl. PGMS) and operating profit 1% above sales growth

Creating value for customers today and in the future by efficient transformation of critical natural resources



Johnson Matthey Inspiring science, enhancing life

Health: Delivering breakout growth

Robert MacLeod, Garrett Dilley and Paul Evans

JM

What you will hear today

Overview of our Health sector and the market we operate in How we create value with our Innovator customers How we create value with our Generics customers

Our strategy and what this will deliver

Health sector to deliver breakout growth

We operate in a growing, \$40bn segment

We have expertise for both Innovator and Generics companies

We have a portfolio of successful products but that portfolio is not yet at scale

We ramped up our investment to broaden the pipeline from 2014

Therefore, sales growth from 2019/20 will be double-digit with margin reaching the high 20%s



Outsourced small molecule API is growing at 8% p.a.

Global sales in API \$170bn ¹



An attractive segment which plays to our strengths



We create value by solving our customers' complex challenges

Our core capabilities:

- Strong brand and position in controlled substances (e.g. opiates and ADHD)
- Proven track record in rapidly developing synthesis routes for APIs with high molecular complexity
- Solid form sciences capability
- Catalyst design and development

What we do:

Overcome challenging problems in the development and manufacture of complex APIs

• Work with both:

- Innovator customers for novel APIs
- Generic customers on known APIs to navigate IP landscape
- Manufacture commercial scale volumes of controlled and non-controlled APIs

Examples of creating value by solving our customers' complex challenges

Example 1: capabilities in developing synthesis routes

Development of complex molecules used to treat a genetic muscular dystrophy disorder

Example 2: solid form science capability that improve bioavailability and saves money

Optimised crystal form of an antiemetic avoided lengthy milling process and improved bioavailability of the API

Our core capabilities:

 Strong brand and position in controlled substances (e.g. opiates and ADHD)

Proven track record in rapidly developing synthesis routes for APIs with high molecular complexity

- Solid form sciences capability
- Catalyst design and development

We will continue to broaden our capabilities in strategically focussed areas

Our business is based on our core capabilities

2016/17 | Sales £243m

JM's existing facilities:

Full range of manufacturing assets in US and Europe

Key development sites in Boston (US) and Cambridge (UK)

Pilot and kilo lab capabilities in China

>1,000 employees


Ramped up investment since 2014 will drive breakout growth

The timelines in the pharma market are long:

Generics projects typically take 4-6 years	Innovator projec	ts take even longer
Opportunity to co-invest to enhance returns	Development risk is taken by the customer	Projects are affected by clinical attrition and novel technology challenges

	2013/14	Today
Sector sales from new products (launched in last 5 years)	0%	19%
Size of pipeline (generic and innovator)	~20 products	~60 products
Annual R&D investment	£8m	£34m

Returns from this investment starts to come through from 2019/20

Our strategy: deliver breakout growth by providing solutions to the complex problems of innovator and generic companies

Trends

Increased demand for high potency drugs

Poor bioavailability profiles

Increased complexity of drugs

Focus

High barrier to entry segments

- Controlled substances
- High potency APIs

Using our high value-add capabilities of

- Developing synthesis routes for complex APIs
- Solid form sciences
- Catalysis enabled API manufacturing

JM strengths

Scale up of complex manufacturing

Materials design and engineering

Materials characteristics and testing

Double-digit sales growth beginning in 2019/20, with margins increasing to high 20%s

Johnson Matthey Inspiring science, enhancing life

Health - How we create value with our **Innovator customers**

Garrett Dilley

JM

We work with innovators on their API challenges

Innovators value chain





Our core capabilities enable access to high-value clinical development projects

Supply of clinical development opens door to commercial manufacture opportunity

JM assists in filing for commercialisation and is listed as manufacturer on regulatory documents

Driving growth through expertise across development to commercialisation

Innovators	% sales	Contractual terms	Sales ranges	Areas of focus
Clinical development – API development and manufacture	42%	6 months - 3 years	£250k - £5m per project	Number of clinical development projects
Commercialised API – development and manufacture	58%	3- 10 years	£1m - £25m p.a. per project	Number of commercialised APIs



Core capabilities: why our customers come to us



Proven track record in rapidly developing synthesis routes for complex APIs

- Solid form sciences
- Catalyst design and development

World class development capabilities in Boston (US) and Cambridge (UK)

Crystal form expertise to rival large pharma – key in solving bioavailability challenges of novel APIs

Pipeline analysis

~60% with "high" molecular complexity or complex transformations/analyses

 \sim 50% highly potent or controlled molecules

~20% contain key catalysis steps

Customers include: Biogen, Nektar and Metacrine

Competitors include: Siegfried, Evonik, Cambrex, Alcami, AMRI, Hovione

Customers come to JM for expertise: an example



JM

Innovators: growth well ahead of the market

We have a strong foundation in the large and growing Innovator outsourced API market

With Innovator customers, we will:

- Continue to grow our product pipeline
- Increasingly convert these to commercial-scale API manufacturing

We will add new skills and expand capacity

This will deliver growth well ahead of the market



Johnson Matthey Inspiring science, enhancing life

Health - How we create value with our Generics customers

Paul Evans

JM

We develop and manufacture complex, high value APIs

Generics value chain 2 - 7 years 3 - 4 years ongoing **FDF and API scale-up Commercialisation API development FDF¹ development** Reformulation and formulation and formulation and process transfer **Regulatory approval** process JM API development and manufacturing* API manufacturing** *small scale quantities **commercial scale quantities \$29 billion global \$140 billion brand value Generics partners work with us Generic companies coming off patent over to access the same strengths include: Teva, Mylan, outsource API next 5 years that innovators value Sandoz, Par and Amneal market

JM competitors include: Alcami, AMRI, Cambrex, Hovione, Noramco, Mallinckrodt and Siegfried

JM

US market characteristics

Indicative drug product lifecycle



Our current portfolio will deliver low single-digit growth

Current product portfolio

	API area	% of sales	Characteristics	JM focus	JM medium-term growth
	Bulk opiates (principally pain relief)	18%	Lower margin	 Improve efficiency Annan site	Flat
Controlled substances	Specialist opiates (pain relief & addiction therapy)	31%	Higher marginPositioned for new customer launches	Improve efficiency	Mid-single digits
	ADHD	24%	Higher marginDeclining past profit shares in near-term	Improve efficiency	Low to mid-single digits
Non- controlled	Diverse therapeutic areas	27%	Higher margin	Drive value	Low

Building our portfolio: our API product pipeline approach

	2 months to 2 years		3 to 4 years	2 to 7 years
Identify opportunities	Screen for fit	Strategy and valuation	Development	Commercialisation
 Continuous monitoring Customer / partner inquiries 	 JM technical advantage Expected market value Competitive and IP landscape 	 Technical development plan IP solutions Commercial positioning and timing 	 API optimisation and scale-up Drug product partner selection Drug product formulation and scale-up Clinical bioequivalence 	Regulatory filingPatent litigationLaunch prep

Disciplined go/no-go decisions with risk-based financial analysis to support decisions and prioritisation

Our API product pipeline will deliver Health's breakout growth

Investment	Capitalised investment of c.£25m per year Investment per product £3m to £10m
Progress	 Over 40 API products in the pipeline: Around 15 in early stages Around 20 in formulation development Around 5 in regulatory approval stage Over the next three to four years, we expect 14-22 of these to launch and a further 20 to be pending regulatory approval
Returns	Not all projects will be successful Wide range of product profitability

Building expanded and balanced portfolio

Ramped-up investment drives our pipeline



Year 2013/14 2014/15 2015/16 2016/17 2017/18 2018/19 2019/20 2020/21 2021/22 2022/23 2023/24 2024/25

JM

Generics pipeline delivers the break out growth in our Health sector



Current pipeline will deliver c.£100m operating profit by 2025, additional pipeline will add to this in outer years

Example: development of dofetilide

Development started in 2011

Developed an innovative and non-infringing route & polymorph Significant financial contribution in 2016/17

JM shares drug

product profits

No other generic has entered the market yet

Utilised solid form sciences and high potency manufacturing capabilities Partner launched in June 2016 achieving first US generic approval and 180-days market exclusivity



JM

Images sourced from https://www.maynepharma.com/products/us-products/generic-products/generic-productscatalog/dofetilide-capsules/

Generics summary

Strong position today in controlled substances Ramped up investment to grow product portfolio since 2014

- We will drive value from our existing product portfolio
- We will deliver growth from our strong product pipeline
- This will deliver substantial growth from 2019/20



Johnson Matthey Inspiring science, enhancing life

Conclusion: Delivering breakout growth

Robert MacLeod

JM

Our Innovator and Generics businesses deliver success together

Innovators

Enhance our position as a technology partner-of-choice
 > Delivering well above market growth

Generics

- Drive value from existing business
 - > Delivering low single-digit growth
- Deliver growth from strong API pipeline
 - > Delivering operating profit of c.£100m in 2024/25

Long-term investment commitment required

Maintain R&D at c.£25m p.a. to expand generic pipeline further

Continue to build our capabilities to meet critical technical challenges – e.g. high potency APIs

Further enhance our capacity as we convert pipeline

Overall capex investment (excl. R&D) c.£30-40m p.a.

Health sector to deliver breakout growth

We operate in a growing, \$40bn segment

We have expertise for both Innovator and Generics companies

We have a portfolio of successful products but that portfolio is not yet at scale

We ramped up our investment to broaden the pipeline from 2014

Therefore, sales growth from 2019/20 will be double-digit with margin reaching the high 20%s



Johnson Matthey Inspiring science, enhancing life

Delivering shareholder value

20000000

Anna Manz **Chief Financial Officer**

Delivering long term shareholder value through:



Relentless focus on driving efficiency Rigorous resource allocation

Guidance for 2017/18:

Sales growth broadly in line with the 6% delivered in H2 2016/17

Improving operating performance offset by non cash items

Restructuring benefit of £10m in the year, with an annualised benefit of £25m

Capex £285m, 1.8x depreciation

Our strong market positions and legislation deliver sustained growth

Growth driven by Europe in next 2 years with share gains and increasing profitability of gasoline and gasoline hybrid

Subsequently, growth driven by legislation in Asia

Investment in capacity will transition from Europe to Asia

Margins maintained through efficiency

Sustained growth in Clean Air



Attractive high growth opportunities

Maintain investment to build a broader, deeper pipeline

In medium term growth accelerates to double digit as we start to benefit from the generic pipeline investment

Margin improves significantly as scale builds

Breakout growth in Health



Market opportunity is substantial and at an early stage

Our technology is market leading and customer feedback is strong

Continue to invest ahead with ~£200m investment in capacity beginning in 2018/19

Expect commercial sales from 2021/22

Breakout growth in Battery Materials



Highly selective investment choices allows us to out perform markets by 1ppt

Focus on operational efficiency improves margins, growing operating profit ahead of sales growth by 1ppt

2018/19 benefits from annualised restructuring savings

Maintaining current levels of investment

Market leading growth in Efficient Natural Resources



Driving sustained improvements in how we run our business

Improve performance through common standards and processes, enabled by IT

£50m, mainly procurement savings, over 3 years to invest and enhance margin

Improving working capital management





Common procurement standards reduce costs to invest and enhance margin



We create value by investing in our technology through three stages

Stage	Clean Air	Efficient Natural Resources	Health
Selectively invest through New Markets sector	e.g. Battery Materials	e.g. Agrochemicals	e.g. Medical Devices
Scale-up	e.g. Emission Control in Asia	e.g. PGM Refining in China	e.g. API Manufacturing in both Innovators and Generics
Sustain and grow	e.g. Emission Control in Europe & NA	e.g. Hydrogen catalysts	_

Our rigorous resource allocation framework

	R&D as % sales	Capex: Depn	ROIC
Select	Meaningful early stage R&D investment	Investment Ahead	<0%
Scale-up	>5%	>1.5	>WACC
Sustain and grow	4-5%	1-1.5	>20%

Consistent investment weighted to near term

R&D remains ~6% of sales

Capex Investment ~1.8x depreciation over the medium term

18/19 increase in capex with Battery Material capacity investment

Rigorous Resource Allocation



Capital allocation



Net Debt* : EBITDA 1.5-2.0x

Growth and value creation will deliver attractive returns

Expanding group ROIC to 20%

Delivering mid to high single digit EPS CAGR

And continuing a progressive dividend policy





Sustained growth and value creation



Be one of the best performing, most trusted and admired speciality chemicals companies in the world

Johnson Matthey Inspiring science, enhancing life

www.matthey.com/investor

00000000